The estimated Net Worth of Penka Petrova is at least $98 ezer dollars as of 8 April 2021. Penka Petrova owns over 5,312 units of Trillium Therapeutics Inc stock worth over $97,953 and over the last 4 years Penka sold TRIL stock worth over $0.
Sign up
Penka Petrova TRIL stock SEC Form 4 insiders trading
Penka has made over 6 trades of the Trillium Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Penka exercised 5,312 units of TRIL stock worth $9,562 on 8 April 2021.
The largest trade Penka's ever made was exercising 5,820 units of Trillium Therapeutics Inc stock on 8 February 2021 worth over $14,317. On average, Penka trades about 3,181 units every 13 days since 2021. As of 8 April 2021 Penka still owns at least 5,312 units of Trillium Therapeutics Inc stock.
You can see the complete history of Penka Petrova stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Penka Petrova's mailing address?
Penka's mailing address filed with the SEC is C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA, A6, L5L 1J9.
Insiders trading at Trillium Therapeutics Inc
Over the last 4 years, insiders at Trillium Therapeutics Inc have traded over $0 worth of Trillium Therapeutics Inc stock. The most active insiders traders include Paul Edward Walker, Helen Katrina Tayton Martin és Paolo Pucci. On average, Trillium Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $220,616. The most recent stock trade was executed by Robert Uger on 7 July 2021, trading 3,646 units of TRIL stock currently worth $1,094.
What does Trillium Therapeutics Inc do?
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.
What does Trillium Therapeutics Inc's logo look like?
Complete history of Penka Petrova stock trades at Trillium Therapeutics Inc
Trillium Therapeutics Inc executives and stock owners
Trillium Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Bhaskar Sen,
Non-Executive Independent Director -
Jitendra Mamtora,
Executive Non-Independent Chairman of the Board -
Satyen Mamtora,
Managing Director, Executive Non-Independent Director -
Karuna Mamtora,
Non-Independent Executive Director -
Sureshchandra Agarwal,
Non-Executive Independent Director -
Subir Das,
Independent Director -
Rakesh Kiri,
Compliance Officer, Company Secretary -
Ramesh Birajdar,
Chief Financial Officer -
Robert Uger,
Chief Scientific Officer -
Penka Petrova,
Chief Development Officer -
Jan Skvarka,
President and CEO -
James T. Parsons,
Chief Financial Officer -
Scott Dunseth Myers,
Director -
Benjamin Looker,
General Counsel -
Catherine J Mackey,
Director -
Luke M Beshar,
Director -
Michael E. Kamarck,
Director -
Helen Katrina Tayton Martin,
Director -
Ingmar Bruns,
Chief Medical Officer -
Rosemary Harrison,
See Remarks -
Paolo Pucci,
Director -
Paul Edward Walker,
Director